

Clerk of the House of Representatives
 Legislative Resource Center
 B-106 Cannon Building
 Washington, DC 20515
<http://lobbyingdisclosure.house.gov>

Secretary of the Senate
 Office of Public Records
 232 Hart Building
 Washington, DC 20510
<http://www.senate.gov/lobby>

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual

BAYER CORPORATION

2. Address

Address1 701 Pennsylvania Ave., NW Suite 720

Address2 _____

City WASHINGTON

State DC

Zip Code 20004

Country USA

3. Principal place of business (if different than line 2)

City _____ State _____ Zip Code _____ Country _____

4a. Contact Name

Ms. EMILY HARRIS

b. Telephone Number

2027378900

c. E-mail

emily.harris@bayer.com

5. Senate ID#
5632-12

7. Client Name

Self

Check if client is a state or local government or instrumentality

BAYER CORPORATION

6. House ID#
312570000

TYPE OF REPORT

8. Year 2012 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date _____

11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000

\$5,000 or more \$ _____

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000

\$5,000 or more \$ 1,450,321.00

14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Digitally Signed By: Ronald F. Docksai, Ph.D. Vice President Federal Government Relations

Date

07/20/2012

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

HR 965/S1211 The Federal Food, Drug and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II; General provisions in the bill)
S 1053 Veterinary Services Investment Act; (General support of the bill)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

HR 872 Reducing Regulatory Burdens Act of 2011; (Provisions related to NPDES permits.)
 S 3240 Agriculture Reform, Food and Jobs Act of 2012; (Provisions related to NPDES permits; provisions relating to pesticides, biotechnology, agriculture research and conservation.)
 S 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013; (All provisions related to funding of USDA agencies including APHIS and FAS.)
 Regulatory Biotech Issues (no bill numbers); (Provisions in proposed regulations regarding the approval of biotech traits and all other issues related to biotech regulations.)
 ESA (no bill); (NMFS Biological opinions -- Discussions on National Marine Fisheries Biological Opinions and their potential affects on agriculture and the need for a resolution to the consultation process.)
 Spray Drift (no bill number); (Discussions on proposed EPA guidance for pesticide label language on preventing spray drift.)
 PRIA (no bill number); (Discussions on EPA regarding reauthorization of the Pesticide Registration Improvement Act (PRIA).)
 Farm Bill (no bill number); (Discussion draft of House Farm bill; (Provisions related to NPDES, PRIA, Pollinators.)
 Bee Health (no bill number); (Discussions on EPA regulatory actions involving pollinator protection and bee health.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean D.	Reimers			<input type="checkbox"/>
Jennifer	Spurgat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

HR 525 Veterinary Public Health Amendments Act: An act to amend the Public Health Service Act to enhance and increase the number of veterinarians trained in veterinary public health; (General provisions in the bill.)

S 518 Veterinary Loan Repayment Program; (In support of legislation.)

HR 1733/S 886 Interstate Horseracing Act 2011; (Definition of performance medicines in Sec. 9.)

HR 1406 Fairness to Pet Owners Act 2011; (General provision requiring veterinary prescribing.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

HR 5973 FY 2013 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act; (General provisions of the bill related to animal drugs and biologics.)
HR 5855 Department of Homeland Security Appropriations Act, 2013; (Support for National Biodefense and Agriculture Facility funding.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

S 2375 Agriculture Appropriations for FY 2012; (Provisions related to agriculture and farm bill programs.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean D.	Reimers			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Redacted]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BAN

16. Specific lobbying issues

HR 2779 Dodd-Frank Banking Regulations 2012 Amendments; (Provisions relating to OTC Derivatives "end user" waivers.)
Policy on Comprehensive Tax Reform (No bill number); (Provisions relating to tax reform legislation.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Ronald F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

HR 901 Full Implementation of the "Chemical Facility Anti-Terrorism Security (CFATS) Authorization Act of 2011"; (All provisions related to implementation of the CFATS program.)

S 847 Safe Chemicals Act of 2011: A bill to modernize and extend the Toxic Substance Control Act of 1976; (All provisions related to safety standard, testing, rules, listing, manufacturing, distribution and product stewardship.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

HR 1249/S 23 A bill to reform the US Patent and Trademark office: Bill would change several key provisions, including first to file, establish an excess fee fund, and broaden the scope of prior user rights; (All provisions related to first to file, fees and prior user rights.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Redacted]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code EDU

16. Specific lobbying issues

S 518 Veterinary Loan Repayment Program; (In support of legislation.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

HR 480 Safe Exploration coming from Underwater Reserves of Energy Act, or the SECURE Act: Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010; Eliminates need for review by the Bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statutes such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972; (All provisions related to off-shore drilling and exploration.)

S 352 American Energy Independence and Security Act of 2011: A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.)

S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.)

S 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.)

S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provision of incentives for alternative power.)

S 398 A bill to increase energy efficiency and other purposes: The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production; (All provisions related to enhancing energy efficiency.)

HR 2962/S 1575 Roofing Efficiency Jobs Act of 2011: A bill to amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. Defines "qualified energy-efficient cool roof replacement property" as any roof system that: (1) is placed in service above conditioned or semi-heated space on an eligible commercial building, (2) replaces an existing roof system, (3) is a low-slope roof, and (4) includes insulation meeting specified standards and a primary roof covering that has a cool roof surface; (All provisions related to the bill.)

S 1737 Sensible Accounting to Value Energy Act of 2011: A bill to improve the accuracy of mortgage underwriting used by mortgage agencies by ensuring that energy costs are included in the underwriting process, to reduce the amount of energy consumed by homes, to facilitate the creation of energy efficiency retro-fit and construction jobs, and for other purposes; (All provisions of the bill.)

HR 2599 PACE Assessment Protection Act of 2011: A bill to prevent Fannie Mae, Freddie Mac, and other federal residential and commercial mortgage lending regulators from adopting policies that contravene established state and local property assessed clean energy laws; (All provisions of the bill.)

S 398 Energy Efficiency National Consensus Appliance Agreement Act; (Provisions related to energy tax credits.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>
Ronald F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

S 231 EPA Stationary Source Regulations Suspension Act: A bill to delay for 2 years, implementation of EPA's regulatory program on greenhouse gases; (All provisions related to greenhouse gas regulations.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Large empty rectangular box for listing foreign entities]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Redacted]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code GOV

16. Specific lobbying issues

S 3187 Food and Drug Administration Safety and Innovation Act; (Provisions related to medical devices.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Robert D.	Thomas			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

HR 432/ S136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

HR 4223 The "Safe Doses Act"; (All provisions of the bill.)

HR 3668 The "Counterfeit Drug Penalty Enhancement Act of 2011"; (All parts.)

HR 4216 The "Foreign Counterfeit Prevention Act"; (All parts.)

Draft Discussion of FDA User Fees; (All parts)

S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.)

Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.)

HR 2245 the Preserving Access to Life Saving Medications Act; (Provisions relating drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.)

HR 965/S 1211 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions of the bill.)

HR 436 Health Care Cost Reduction Act of 2012; (Provisions related to medical device taxes.)

Safe Injection Practices (no bill number); (Provisions related to safer injection practices.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>
Thomas B.	Lilburn			<input type="checkbox"/>
Julie	Corcoran			<input type="checkbox"/>
Robert D.	Thomas			<input type="checkbox"/>
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

HR 901/ HR 908/HR 916/S 473 Chemical Facility Anti-Terrorism Security Authorization Act of 2011; (Provisions related to extensions of CFATS.)
S 709 Secure Chemical Facilities Act: A bill to insure adequate security is employed at chemical plants; (All provisions related to chemical risk management, tiered assessments, audits, standard setting and inspections.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jennifer	Spurgat			<input type="checkbox"/>
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

S 365 Balance Budge Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas B.	Lilburn			<input type="checkbox"/>
Julie	Corcoran			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Redacted]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MAN

16. Specific lobbying issues

S 3187 Food and Drug Administration Safety and Innovation Act; (Provisions relating to medical devices.)
Safe Injection Practices (no bill number); (Provisions related to safer injection practices.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Robert D.	Thomas			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

S 3187 Food and Drug Administration Safety and Innovation Act; (Provisions related to medical devices.)
Safe Injection Practices (no bill number); (Provisions related to safer injection practices.)
HR 1733/S 886 Interstate Horseracing Act 2011; (Definition of performance medicines in Sec. 9.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Robert D.	Thomas			<input type="checkbox"/>
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

HR 4223 The "Safe Doses Act"; (All parts.)
HR 3668 The "Counterfeit Drug Penalty Enhancement Act of 2011"; (All provisions.)
HR 4216 The "Foreign Counterfeit Prevention Act"; (All provisions.)
Draft Discussion on FDA User Fees; (All provisions.)
Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic report and stop sale.)
HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.)
Meth Lab Elimination Act of 2010, a draft by Senator Wyden; (All parts relating to pseudoephedrine.)
Maintaining Consumer Access to Cough Medicine Act of 2011, a draft; (All parts relating to DXM.)
HR 525 Veterinary Public Health Amendments Act: An act to amend the Public Health Service Act to enhance and increase the number of veterinarians trained in veterinary public health.)
HR 1406 Fairness to Pet Owners Act 2011; (General provisions requiring veterinary prescribing.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas B.	Lilburn			<input type="checkbox"/>
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

--

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code RRR

16. Specific lobbying issues

S 158 Surface Transportation reauthorization Act 2009: A bill to reauthorize the Surface Transportation Act and for other purposes; (All provisions related to bottleneck provisions, common carrier, injunctive relief, rate quotation, competition, and serve necessary to business and public interest.)
 S 49 The Railroad Antitrust Enforcement Act of 2011: A bill to amend Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

--

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

HR 901/HR 908/HR 916/S 473 Chemical Facility Anti-Terrorism Security Authorization Act of 2011; (Provisions related to extensions of CFATS.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jennifer	Spurgat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAR

16. Specific lobbying issues

S 3292 Temporary Duty Suspension Process Act of 2012; (Provisions related to tariffs.)
 H.R.4459 and S. 2725: To suspend temporarily the duty on Thidiazuron; (Provisions related to tariffs.)
 H.R.4460 and S. 3135 : To extend the suspension of duty on Fenamidone; (Provisions related to tariffs.)
 H.R.4461 and S.2702 : To extend the suspension of duty on Spirodiclofen; (Provisions related to tariffs.)
 H.R.4462 and S.3137 : To extend the suspension of duty on 2,4-dichloroaniline; (Provisions related to tariffs.)
 H.R.4463 and S.2723: To suspend temporarily the duty on Thiacloprid; (Provisions related to tariffs.)
 H.R.4464 and S. 2700: To extend the suspension of duty on Pyrimethanil (Provisions related to tariffs.)
 H.R.4465 : To suspend temporarily the duty on Pyrasulfotole; (Provisions related to tariffs.)
 H.R.4466 and S.2704: To suspend temporarily the duty on Fosetyl-Al; (Provisions related to tariffs.)
 H.R.4538 and S.3020 : To extend the temporary suspension of duty on Permethrin; (Provisions related to tariffs.)
 H.R.4575 : To modify and extend the temporary reduction of duty on Isoxaflutole; (Provisions related to tariffs.)
 H.R.4576 and S.3015 : To modify and extend the temporary reduction of duty on Clothianidin; (Provisions related to tariffs.)
 H.R.4578 and S. 3016: To suspend temporarily the duty on Triadimefon; (Provisions related to tariffs.)
 H.R.4657 : To suspend temporarily the duty on mixtures containing β -cyfluthrin; (Provisions related to tariffs.)
 H.R.4658 : To extend the temporary reduction of duty on Deltamethrin; (Provisions related to tariffs.)
 H.R.4660 : To reduce temporarily the duty on Thiencarbazone-methyl; (Provisions related to tariffs.)
 H.R.4661 and S.3017: To extend the temporary suspension of duty on Spiromesifen; (Provisions related to tariffs.)
 H.R.4662 : To suspend temporarily the duty on Trifloxystrobin; (Provisions related to tariffs.)
 H.R.4663 and S. 2703: To modify and extend the temporary reduction of duty on 2-Acetylbutrolactone; (Provisions related to tariffs.)
 H.R.4664 : To suspend temporarily the duty on 1,3-Cyclohexanedione; (Provisions related to tariffs.)
 H.R.4665 and S. 3132: To suspend temporarily the duty on Flubendiamide; (Provisions related to tariffs.)
 H.R.4666 and S.2722 : To suspend temporarily the duty on Spirotetramat; (Provisions related to tariffs.)
 H.R.4667 : To extend the temporary suspension of duty on Isoxadifen-Ethyl; (Provisions related to tariffs.)
 H.R.4668 and S. 3024: To extend the temporary suspension of duty on Cyfluthrin; (Provisions related to tariffs.)
 H.R.4669 : To modify and extend the temporary reduction of duty on β -cyfluthrin; (Provisions related to tariffs.)
 H.R.4670 : To reduce temporarily the duty on mixtures containing Trifloxystrobin and Prothioconazole; (Provisions related to tariffs.)
 H.R.4671 : To suspend temporarily the rate of duty on certain mixtures containing Trifloxystrobin; (Provisions related to tariffs.)
 H.R.4672 and S.2726 : To reduce temporarily the duty on mixtures containing Spirotetramat; (Provisions related to tariffs.)
 H.R.4673 : To suspend temporarily the duty on mixtures containing Trifloxystrobin and Propiconazole; (Provisions related to tariffs.)
 H.R.4675 and S. 2678: To reduce temporarily the duty on 1H-[1,2,4]Triazole; (Provisions related to tariffs.)
 H.R.4676 and S. 3161 : To suspend temporarily the duty on mixtures of Indaziflam; (Provisions related to tariffs.)
 H.R.4677 and S. 3162: To suspend temporarily the duty on mixtures of Flubendiamide; (Provisions related to tariffs.)
 H.R.4678 and S. 2681: To suspend temporarily the duty on mixtures containing Fluopyram; (Provisions related to tariffs.)
 H.R.4679 and S. 2719: To suspend temporarily the duty on mixtures containing Fluopyram and Prothioconazole; (Provisions related to tariffs.)
 H.R.4680 and S.2720: To suspend temporarily the duty on mixtures containing Fluopyram and Trifloxystrobin; (Provisions related to tariffs.)
 H.R.4681 and S.2721 : To suspend temporarily the duty on mixtures containing Fluopyram and Pyrimethanil; (Provisions related to tariffs.)
 H.R.4682 and S. 3133: To suspend temporarily the duty on Fenhexamid; (Provisions related to tariffs.)
 H.R.4683 and S.3134: To suspend temporarily the duty on Fluopicolide; (Provisions related to tariffs.)
 H.R.4684 and S 3130: To suspend temporarily the duty on Fluopyram; (Provisions related to tariffs.)
 H.R.4685 and S. 3131 : To suspend temporarily the duty on Indaziflam; (Provisions related to tariffs.)
 H.R.4686 and S. 3021 : To extend the temporary suspension of duty on 4-Chlorobenzaldehyde; (Provisions related to tariffs.)
 H.R.4687 and S.2701 : To extend the temporary suspension of duty on Phenmedipham; (Provisions related to tariffs.)
 H.R.4694 and S.3160 : To reduce temporarily the duty on product mixtures containing Spiromesifen; (Provisions related to tariffs.)
 H.R.4696 : To suspend temporarily the duty on product mixtures containing Clothianidin; (Provisions related to tariffs.)
 H.R.4698 : To extend the suspension of duty on product mixtures containing ethofumesate; (Provisions related to tariffs.)
 H.R.4699 : To suspend temporarily the duty on cyprosulfamide; (Provisions related to tariffs.)
 H.R.4735 and S.2355 : To extend and modify the temporary reduction of duty on ACM; (Provisions related to tariffs.)
 H.R.4736 and S.2356: To reduce temporarily the duty on Glufosinate-Ammonium (GA); (Provisions related to tariffs.)
 H.R.4737 and S.2354 : To extend and modify the temporary reduction of duty on Oxadiazon; (Provisions related to tariffs.)
 H.R.4876 and S. 3136: To extend the temporary reduction of duty on Imidacloprid; (Provisions related to tariffs.)
 H.R.4878 and S. 2587 : To suspend temporarily the duty on 1-Naphthyl, N-methylcarbamate; (Provisions related to tariffs.)
 H.R.4879 and S.2386 : To reduce temporarily the duty on Penflufen; (Provisions related to tariffs.)
 H.R.4883 and S. 2385 : To suspend temporarily the duty on IMIDACLOPRID; (Provisions related to tariffs.)
 H.R.4914 and S. 2680: To suspend temporarily the duty on mixtures containing Fluopyram and Tebuconazole; (Provisions related to tariffs.)
 HR5592/S 3023 To suspend temporarily the duty on mixtures containing beta-cyfluthrin; (Provisions related to tariffs.)
 HR5591/S 3025 To modify and extend the temporary reduction of duty on beta-cyfluthrin; (Provisions related to tariffs.)
 HR 4695/S 3008 To reduce temporarily the duty on product mixtures containing Clothianidin and Bacillus Firmus strain I-1582; (Provisions related to tariffs.)
 HR4874/S 2382 To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxaflutole, and Cyprosulfamide; (Provisions related to tariffs.)
 HR 4659 To suspend temporarily the duty on N-(4-Fluorophenyl)-2-hydroxy-N-(1-methylethyl)acetamide; (Provisions related to tariffs.)

HR 4877 To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its ?-Cyfluthrin isomer; (Provisions related to tariffs.)
 HR 5565/S 2384 To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its beta-Cyfluthrin isomer; (Provisions related to tariffs.)
 HR 4875/S 2383 To modify and extend the temporary reduction of duty on mixtures of imidacloprid with application adjuvants; (Provisions related to tariffs.)
 HR 4873/S 2381 To suspend temporarily the duty on mixtures containing Imidacloprid and Thiodicarb; (Provisions related to tariffs.)
 HR 4577 To extend and modify the temporary reduction of duty on mixtures containing Isoxaflutole and Cyprosulfamide; (Provisions related to tariffs.)
 HR 5257/S 3009 To extend the temporary suspension of duty on product mixtures containing mesosulfuron-methyl; (Provisions related to tariffs.)
 HR 4537/S 3019 To suspend temporarily the duty on Methyl 2-[(4-methyl-5-oxo-3-propoxy-4,5-dihydro-[1,2,4]triazole-1-carbonyl)sulfamoyl]benzoate, sodium salt; (Provisions related to tariffs.)
 HR 4536/S 3018 To extend the temporary suspension of duty on 2-Chlorobenzyl chloride; (Provisions related to tariffs.)
 HR 5258/S 3022 To suspend temporarily the rate of duty on certain mixtures containing Fenoxaprop-p-ethyl, Pyrasulfotole, Bromoxynil octanoate, Bromoxynil heptanoate, and Mefenpyr-diethyl; (Provisions related to tariffs.)
 HR 4697 To reduce temporarily the duty on product mixtures containing Pyrasulfotole, Bromoxynil Octanoate, and Bromoxynil Heptanoate, including application adjuvants; (Provisions related to tariffs.)
 HR 4574 To modify and extend the temporary reduction of duty on AE 0172747 Ether; (Provisions related to tariffs.)
 HR 4579 To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxadifen-ethyl, and Tembotrione; (Provisions related to tariffs.)
 H.R.4580 To suspend temporarily the duty on mixtures containing Trifloxystrobin, Clothianidin, Carboxin, and Metalaxyl; (Provisions related to tariffs.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean D.	Reimers			<input type="checkbox"/>
Jennifer	Spurgat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

--

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAR

16. Specific lobbying issues

HR 5250/S 2763 To suspend temporarily the rate of duty on dimethyl carbonate polymer with 1,6-hexanediol copolymer and 2-oxepanone; (Provisions related to the reduction of tariffs.)
 HR 5251/S 2765 To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs.)
 HR 5250/S 2767 To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs.)
 HR 5253/S 2770/S 2778 To suspend temporarily the duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent; (Provisions related to the reduction of tariffs.)
 HR 5236/S 2772 To suspend temporarily the duty on Desmodur BL 1100/1; (Provisions related to the reduction of tariffs.)
 HR 5235/S 2773 To suspend temporarily the duty on Bayhydur BL 5335; (Provisions related to the reduction of tariffs.)
 HR 5233/S 2775 To suspend temporarily the duty on Desmodur VP LS 2078/2; (Provisions related to the reduction of tariffs.)
 HR 5229/S 2779 To suspend temporarily the duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked (Provisions related to the reduction of tariffs.)
 HR 5234/S 2781 To suspend temporarily the duty on Bayhydur XP 2547; (Provisions related to the reduction of tariffs.)
 HR 5246/S 2783 To extend the temporary suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked; (Provisions related to the reduction of tariffs.)
 HR 5247/S 2788 To extend and modify the temporary suspension of duty on Desmodur R-E; (Provisions related to the reduction of tariffs.)
 HR 5230/2784 To extend the temporary suspension of duty on Desmodur E 14; (Provisions related to the reduction of tariffs.)
 HR 5248/S 2760 To extend and modify the temporary suspension of duty on Poly(toluene diisocyanate); (Provisions related to the reduction of tariffs.)
 HR 5249/S 2762 To extend and modify the temporary suspension of duty on Desmodur RF-E; (Provisions related to the reduction of tariffs.)
 HR 5231/S 2786 To extend and modify the temporary suspension of duty on Desmodur HL BA; (Provisions related to the reduction of tariffs.)
 HR 5276/S 2758 To extend and modify the temporary reduction of duty on o-Acetylsalicylic acid (Aspirin); (Provisions related to the reduction of tariffs.)
 HR 5277/S 3028 To extend the temporary suspension of duty on D-Mannose; (Provisions related to the reduction of tariffs.)
 HR 5278/S 3026 To extend the temporary suspension of duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate); (Provisions related to the reduction of tariffs.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

HR 436 Healthcare Cost Reduction Act of 2012; (Provisions related to medical device tax.)
S 398 Energy Efficiency National Consensus Alliance Agreement Act of 2011; (Provisions relating to energy tax credits.)
HR 527 Regulatory Reform Improvement Act of 2011; (Provisions relating to reducing the regulatory process timeline.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Robert D.	Thomas			<input type="checkbox"/>
Ronald F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

[Redacted]

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRA

16. Specific lobbying issues

HR 658 FAA Modernization and Reform Act of 2012; (Provisions related to transportation of lithium cells and batteries.)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New <input type="checkbox"/>
Robert D.	Thomas			

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1 Jennifer	Spurgat	5			
2		6			
3		7			
4		8			

ISSUE UPDATE

24. General lobbying issue that no longer pertains

_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	City	State/Province	Zip	
				City	State
					Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1	3	5
2	4	6

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address City State/Province Country	City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	5	9
2	6	10
3	7	11
4	8	12